Press Release

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium

Late-breaker abstract recently submitted to the Multinational Association of Supportive Care in Cancer (MASCC) shows additional significant results for breast cancer subgroup

The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025, and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022

Read More
Press Release

SouthGobi Announces Profit Alert

Read More
DEA Delays Threaten U.S. Leadership in Global Cannabis Pharma Market Despite FDA Advances
Press Release

DEA Delays Threaten U.S. Leadership in Global Cannabis Pharma Market Despite FDA Advances

Duane Boise, CEO of MMJ International Holdings, expressed frustration over the contrasting approaches of federal agencies, stating, "While the FDA is facilitating medical innovation, the DEA's hindrance not only blocks scientific progress but also contradicts directives aimed at revitalizing domestic manufacturing." This situation starkly contrasts with the "Buy American" initiative endorsed by President Trump in 2020, which was intended to strengthen U.S. drug production capabilities and reduce dependence on foreign manufacturers.

Read More
Press Release

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference

Click here to register for Jaguar's March 31 investor webcast

Company plans to file its annual report on March 31, 2025 on Form 10-K for the year ended December 31, 2024

Read More